About this trial
Postoperative pain after laparoscopic cholecystectomy can be considerable. Regional techniques such as erector spinae plane (ESP) block or transversus abdominis plane (TAP) block may be suitable for patients at increased risk of postoperative pain. The deep rectus sheath block is a novel block which is a modified version of the conventional rectus sheath block. It was reported in a few case reports that, it may be used for postoperative analgesia in patients undergoing laparoscopic cholecystectomy. The aim of this study is to investigate the postoperative analgesic efficacy of deep rectus sheath block in patients undergoing laparoscopic cholecystectomy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age between 18 and 80 years
Patients with American Society of Anesthesiology (ASA) physical status I-II
Patients scheduled for a laparoscopic cholecystectomy
Disqualifiers
Allergy to local anesthetics
Coagulopathy
Skin infection at the deep rectus sheath block area
Advanced hepatic or renal failure
Trial design
Parallel
Treatments tested in this trial
Intravenous morphine patient control analgesia
Other intervention24-hour morphine consumption will be recorded
Intravenous patient control analgesia
Other intervention24-hour morphine consumption will be recorded
Deep rectus sheath block
Other interventionDeep rectus sheath block will be administered at the end of the surgery.
Treatment groups
Trial outcomes
Primary outcomes
Morphine consumption
The amount of morphine required by the patient and given by the device will be recorded for the first 24 hours.
Secondary outcomes
Postoperative numerical rating scale scores
Postoperative pain will be assessed using a numerical rating scale (NRS) (from 0 = no pain to 10 = maximum possible pain) for the first 24 hours.
Rescue analgesic drug requirement
The amount of rescue analgesic in mg required by the patient will be recorded for the first 24 hours.
Incidence of postoperative nausea and vomiting
Number of patients developing postoperative nausea and vomiting will be recorded for the first 24 hours
Sponsors and contacts
Click on the lead sponsor to view all of their trials.